Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation Allogeneic stem cell transplantation (SCT) with reducedintensity conditioning (RIC) has been demonstrated to be effective in achieving long-term disease-free survival with an acceptable toxicity in older patients with myelofibrosis, and patients often demonstrate reversal of marrow fibrosis and cytopenias. 1, 2 When disease relapses, patients may benefit from donor lymphocyte infusion (DLI) and achieve remission. 3 The accepted mechanism of this therapy is harnessing of the graft-versus-tumor effect (GvT); however, it may be associated with graft-versus-host disease (GVHD) and related morbidity and mortality. Here, we describe a patient with postpolycythemic myeloid metaplasia (PPMM) who relapsed after SCT with a clinical presentation of polycythemia vera (PV) and responded to DLI without demonstrating GVHD. Moreover, analysis of the JAK2-V617F mutation levels correlated with his disease course and demonstrated a 'molecular remission' after receiving DLI.
A 55-year-old man was diagnosed with PV in October 1984. At presentation, he had a hematocrit of 58%, mild leukocytosis, splenomegaly (17 cm on an ultrasound scan) and increased red cell mass by isotope dilution technique. He was treated with recurrent phlebotomy and hydroxyurea to keep his hematocrit at normal limits. Spleen size also decreased with therapy. During the year 2003, hematocrit progressively declined and blood smear showed leukoerythroblastosis with increasing splenomegaly (420 cm). Bone marrow biopsy revealed marked hypercellularity, megakaryocytic hyperplasia with severe dysplasia and a significant increase in reticulin fibers. G-banding revealed normal karyotype. The patient was diagnosed with the spent phase of PV or PPMM. He was treated with hydroxyurea and a short trial of thalidomide; however, his disease progressed and he developed constitutional symptoms including fever, diaphoresis and weight loss. On May 2005, he underwent splenectomy and subsequently was referred to allogeneic peripheral SCT from his human leukocyte antigen-identical male sibling, which took place on October 2005. At that time, he was considered to be at low risk based on Lille score. The JAK2-V617F mutation level measured using a chip-based matrix-assisted laser desorption time-of-flight mass spectrometer analysis was 94%. 4 He was given an RIC consisting of fludarabine (30 mg/m 2 daily, 5 days), intravenous busulfan (0.8 mg/kg 10 Â doses) and antithymocyte globulin, according to the European Group for Blood and Marrow Transplantation protocol. 2 He was then infused with 11 Â 10 6 per kg CD34 þ cells from his human leukocyte antigen-identical brother. Granulocyte recovery of 0.5 Â 10 9 per l was achieved on day þ 13 and a platelet recovery of 420 Â 10 9 per l on day þ 19. He had acute GVHD grade II of the skin and was treated with steroids. He later had limitedstage chronic GVHD of the skin and the liver, but was able to discontinue immune suppression therapy, 14 months after SCT. Complete donor chimerism and the absence of the JAK2-V617F mutation was noted 30 days post-transplantation. Bone marrow biopsy about a year after SCT showed marked regression of myelofibrosis. However, 19 months after SCT, the hematocrit started to increase up to 52.8% and leukocyte and platelet counts increased to 20.8 and 750 Â 10 6 per l, respectively. Peripheral blood and bone marrow analysis revealed mixed chimerism with 60% of donor cells by PCR for microsatellite polymorphism. The JAK2-V617F mutation level was 30%. Bone marrow biopsy showed no increase in the residual degree of fibrosis. This was consistent with relapsed PV. The patient required recurrent phlebotomy and was then treated with three successive DLIs in increasing doses (total CD3 þ cells; 1 Â 10 7 , 5 Â 10 7 and 1 Â 10 8 per kg, respectively) given over 3 months. Hematological response was noted 2 weeks after the third DLI with normalization of blood counts and without the need for further phlebotomy. Concomitantly, a gradual decrease in host chimerism and in the level of the JAK2-V617F mutation was demonstrated. It was assumed that the response to DLI occurred by a GvT effect; however, the patient did not develop GVHD. Four months after the first DLI and 1 month after the third, the patient was found to have full donor chimerism. However, the JAK2-V617F mutation was still detected at low levels until 2 months later (Figure 1) . The patient remained in complete molecular remission, 10 months after the start of DLI.
This case presentation shows a few unique aspects. Patients suffering from PV usually enjoy prolonged survival compared with other myeloproliferative disorders. After a number of years, the erythrocytic phase of the disease frequently becomes inactive and subsequently patients may develop a spent phase or PPMM indistinguishable from idiopathic myelofibrosis. These patients have short survival and their quality of life is compromised by asthenia, increasing splenomegaly, weight loss and anorexia. Chemotherapy can result in return of a malignant disease to the preceding less-advanced phase. Chronic myeloid leukemia in blastic phase may return to chronic phase and secondary acute myeloid leukemia to myelodysplastic syndrome following chemotherapy or at relapse after SCT. However, only rare cases of PPMM have been described in which chemotherapy treatment has resulted in reversed direction of the disease course, with significant decrease in marrow fibrosis associated with the development of an elevated red cell mass, a state indistinguishable from PV. 
Letters to the Editor
The only curative treatment for idiopathic myelofibrosis consistent with reversal of bone marrow fibrosis and normalization of hematopoiesis is allogeneic SCT. The high transplantrelated mortality during standard myeloablative regimens makes this procedure relevant only to young patients in good medical condition. The concept that a GvT effect may be sufficient to obtain disease eradication has made RIC attractive particularly in older patients because of its reduced toxicity. Its beneficial effect has been further illustrated by successful disease eradication with DLI.
1,2 This case shows the strong antimyelofibrosis effect of DLI that can be separated from GVHD and can be effective even in patients with prior history of acute and/or GVHD. In this case, the GvT effect was demonstrated against the recurrent PV clone. This has not been demonstrated commonly as PV is not considered an indication for SCT before further disease progression.
Analysis of donor and recipient chimerism is of utmost importance in predicting engraftment and rejection as well as disease progression after SCT and DLI. 6 Increased mixed chimerism may be a reflection of persistence or recurrence of either leukemic or normal host cells. A variety of techniques have been developed for the detection of mixed chimerism and minimal residual disease. PCR for short tandem repeats using several short tandem repeat loci or for microsatellite polymorphism allows higher than 99% discrimination between donor and recipient; however, its disadvantage is its sensitivity of only 0.1-5%. Malignancy-specific markers may be a better method to detect minimal residual disease, especially after RIC and early after SCT, as residual host non-malignant hematopoiesis can be the cause of low-level host chimerism. The most known of such minimal residual disease testing methods is the quantitative PCR for bcr/abl in chronic myeloid leukemia. Nearly half of the patients with myelofibrosis and most patients with PV have the V617F-JAK2 mutation. 7 Recent studies suggested sensitive quantitative methods for monitoring the V617F-JAK2 mutation level to assess treatment response after allogeneic SCT in patients with myelofibrosis. 4, 8 Our case presentation shows the advantage in sensitivity of this test over the less-specific chimerism testing. Our patient continued to show molecular evidence of disease 2 months after achieving complete donor chimerism, until true molecular remission was achieved with continued GvT effect.
In summary, this case presentation shows a few unique aspects related to SCT in myelofibrosis. It shows that the secondary myelofibrosis process can be reversed and the initial PV clone can dominate at relapse. DLI is effective in restoring remission even in the absence of GVHD and in patients with prior GVHD. The quantitative monitoring of the V617F-JAK2 mutation is an important tool in the follow-up of these patients and determining a molecular remission. Imatinib is a tyrosine kinase inhibitor that has undoubtedly saved and improved the quality of lives of many thousands of patients with chronic myeloid leukaemia (CML). It has become the treatment of choice for newly diagnosed patients in chronic phase, and a recent report suggests that modern drug treatment may produce superior results to allogeneic stem cell transplantation (SCT). 1 The imatinib-treated cohort within the International Randomized Study of Interferon and STI571 (IRIS) has provided valuable information on the longer term effects of imatinib treatment. On 400 mg daily, the overall survival at 5 years is 89%. 2 Furthermore, the IRIS data suggest that the rate of disease progression may decrease with time. However, these data are derived from a clinical trial, and it is therefore important to establish if these results can be reproduced in a more general CML population. Here we present the results of a populationbased study of CML treated with 400 mg daily imatinib in our health-care area.
In our area of the North West of England, the adjacent North Wales coastal strip and the Isle of Man (total population 2 million), all services for adults with haematological cancer are located at 12 hospitals. Molecular diagnosis of CML and monitoring for BCR-ABL transcripts are carried out at a single
